We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+6.45%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.23B
AUM Growth
+$1.54B
Cap. Flow
+$1.36B
Cap. Flow %
42.13%
Top 10 Hldgs %
68.77%
Holding
142
New
24
Increased
22
Reduced
20
Closed
25

Top Buys

Rank Stock Value
1
CAVA icon
CAVA Group
CAVA
+$1.32B
2
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$73.7M
3
SLRN
ACELYRIN
SLRN
+$37.2M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$21.3M
5
MORF
Morphic Holding, Inc. Common Stock
MORF
+$17M

Top Sells

Rank Stock Value
1
WW
WW International
WW
+$61.1M
2
ONC
BeOne Medicines Ltd
ONC
+$20.5M
3
FATE icon
Fate Therapeutics
FATE
+$14.8M
4
APLS
Apellis Pharmaceuticals
APLS
+$14.3M
5
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$13.1M

Sector Composition

Rank Sector Weight
1 Healthcare 54.66%
2 Consumer Discretionary 41.39%
3 Miscellaneous 3.23%
4 Technology 0.24%
5 Financials 0.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GPCR icon
126
Structure Therapeutics
GPCR
$2.74B
– –
-75,000
Closed -$1.78M
IMUX icon
127
Immunic
IMUX
$146M
– –
-127,471
Closed -$1.9M
CYPH
128
Cypherpunk Technologies Inc
CYPH
$236M
– –
-400,000
Closed -$1.36M
PRTA icon
129
Prothena Corp
PRTA
$431M
– –
-2,746
Closed -$133K
TGTX icon
130
TG Therapeutics
TGTX
$8.16B
– –
-511,389
Closed -$7.69M
TSVT
131
DELISTED
2seventy bio
TSVT
– –
-750,000
Closed -$7.65M
TVTX icon
132
Travere Therapeutics
TVTX
$5.9B
– –
-511,784
Closed -$11.5M
VKTX icon
133
Viking Therapeutics
VKTX
$3.52B
– –
-300,000
Closed -$5M
WW
134
DELISTED
WW International
WW
– –
-14,818,300
Closed -$61.1M
KRTX
135
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-1,747
Closed -$317K
KDNY
136
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-258,687
Closed -$5.99M
DICE
137
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
– –
-4,318
Closed -$124K
RXDX
138
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
– –
-121,756
Closed -$13.1M
TCRR
139
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
– –
-750,000
Closed -$1.13M
RUBY
140
DELISTED
Rubius Therapeutics, Inc
RUBY
– –
-2,042,666
Closed -$44K
MTCR
141
DELISTED
Metacrine, Inc. Common Stock
MTCR
– –
-924,898
Closed -$528K
CFRX
142
DELISTED
ContraFect Corporation
CFRX
– –
-18,750
Closed -$34K
2 3 4 5
6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q2 2023 Portfolio in Review

As of Q2 2023, Artal Group held 142 positions worth $3.23B, up 92% from $1.68B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Artal Group deployed $1.36B of net new capital in Q2 2023, opening 24 new positions and adding to 22 existing holdings. Its largest new stake was CAVA Group: 32,007,990 shares worth $1.31B.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 94% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

On the sell side, the largest reduction was BeOne Medicines Ltd, an estimated $20.5M trimmed.

  • Artal Group's largest Q2 2023 buy was CAVA Group: 32,007,990 shares worth $1.31B.
  • Artal Group added most to Lexicon Pharmaceuticals in Q2 2023, an estimated $73.7M increase.
  • Artal Group's biggest Q2 2023 reduction was BeOne Medicines Ltd, cutting an estimated $20.5M.
  • Artal Group fully exited WW International in Q2 2023, selling an estimated $61.1M.
  • Artal Group's ten largest holdings make up 69% of its $3.23B portfolio in Q2 2023.
  • Artal Group opened 24 new positions and closed 25 in Q2 2023.
  • Artal Group's portfolio value rose 92% quarter-over-quarter to $3.23B.

Based on Artal Group's 13F filing for Q2 2023, filed 11 Aug 2023.